Ginkgo Bioworks CEO: Delta Will Be 'Endemic Like the Flu'

The video discusses the largest biotech IPO, highlighting its impact on scaling operations and reducing costs. It explains the concept of programming cells for biotech applications, with examples in vaccine production and cannabinoid synthesis. The discussion shifts to COVID-19, addressing vaccine hesitancy, the delta variant, and public health strategies like testing. Finally, it explores the future potential of mRNA technology in developing new vaccines and therapeutics.

In what ways does the speaker suggest that vaccination strategies may evolve in the future?

What breakthroughs in vaccine technology does the speaker anticipate as a result of mRNA technology?